Directorio
We are doing this study is to collect additional follow-up data and samples from participants who completed the P-RAD clinical trial.
We are doing this study to evaluate the performance of an experimental medical technology called the Patched Sepsis Prediction Algorithm (the study technology). This technology is designed to detect the early signs of sepsis and give clinicians the chance to treat it earlier than usual.
If you choose to join this study, you or your child, will:
- Allow us access to your medical record for up to 5 years
- Answer questions about your health history and current symptoms
- Have a nasal swab
- Give a stool sample
- Complete 3 follow-up phone calls
- Have blood drawn (only if in the hospital or l)
We are doing this study to learn more about how certain vaccines can affect people's polyethylene glycol (PEG) sensitivity levels. PEG is a component of several different vaccines. We want to compare blood samples from healthy volunteers to blood samples from HIV Vaccine Trials Network (HVTN) 133 participants. We hope this will help us better understand the variation of PEG sensitivity in the general population and between vaccinated and unvaccinated individuals.
We are doing this study to find out if pelvic floor physical therapy can improve sexual function for women who have undergone pelvic radiation.
We are doing this study to see if the study drug, dostarlimab, can reduce the recurrence of cancer in people who have had their colon cancer surgically removed.
We are doing this study to understand whether people who receive a lower radiation dose after an interim (the second scan) PET-CT identifies an early treatment response have a similar outcome to those receiving a standard radiation dose. The results of the interim PET-CT scan will be used to guide your radiation dose plan. Depending on the PET-CT results, you will either receive a reduced radiation dose or the standard radiation dose for your cancer.
We are doing this study to find the most effective, safe dose of an experimental drug called PF-0793440 (the study drug). We want to know how well it works on its own and in combination with other drugs for the treatment of different cancers in people who have KRAS mutation(s).